AzTrials
AzTrials

Septic ShockNCT03456180

Changes in Microvascular Perfusion During Blood Purification With Cytosorb® in Septic Shock

An observational study of Septic Shock, run by Università Politecnica delle Marche.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Sepsis is defined as a life-threatening event due to a dysregulated immune response to an host. Blood purification techniques may be considered as a therapeutic weapon to front sepsis and septic shock. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Septic Shock
What is being tested?
Haemoadsorption with Cytosorb cartridge
Type of treatment
Medical device
How many people
10 participants
Where
No sites listed yet
Study dates
9 Dec 2016to 15 Dec 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: patients with septic shock requiring renal replacement therapy for acute renal failure and undergoing haemoadsorption with Cytosorb cartridge

Who may be able to join

  • age>18
  • septic patients with acute kidney failure that need to undergo CHHV treatment.

Who cannot join

  • hypersensitivity or allergy to the components of the cartridge
  • pregnancy
  • maxillary-facial trauma that prohibits mouth access and sublingual microcirculation evaluation.

About this study

Sepsis is defined as a life-threatening event due to a dysregulated immune response to an host. Blood purification techniques may be considered as a therapeutic weapon to front sepsis and septic shock.

Haemoadsorption is one of the known blood purification technique that is employed in this study, and it is based on the principle that whole blood, contacting the surface of proper designed sorbent, would be cleared of certain substrates. With haemoadsorption it is possible to de-circulate from bloodstream high molecular weight substances, such as cytokines.In this study Cytosorb® cartridge, based on haemoadsorption principle is applied on septic patients, suffering for acute kidney failure, along with continuous veno-venous haemodialysis (CVVH-D).Microcirculation has a crucial role in the natural history of sepsis.

Read more

In this prospective observational non interventional study, 10 septic patients with an acute kidney failure that need CVVH are enrolled.

The primary endpoint of the study is to verify an improvement in the density of microcirculatory vessels and in the quality of blood flow after exposure to Cytosorb®. These two parameters are well described synthetically by the Perfused Vessel Density (PVD).

As secondary endpoints we also want to analyze the modification of microcirculation after haemoadsorption therapy: microvascular blood flow, described by the microvascular flow index (MFI) and peripheral tissue oxygen perfusion during Cytosorb® exposure using near infrared spectroscopy technique (NIRS)

Read the detailed description

Introduction Sepsis is defined as a life-threatening event due to a dysregulated immune response to an infection. Blood purification techniques may be considered as a therapeutic weapon to front sepsis and septic shock.

The rationale of blood purification in sepsis is to modulate a dysregulated profile of immune response to the host in order to reduce tissue damage due to over production of pleiotropic pro-inflammatory cytokines.

Blood purification may also control elevated levels of anti-inflammatory cytokines that may lead to a down-modulation of immune system and immunoparalysis.

Haemoadsorption is one of the known blood purification technique that is employed in this study, and it is based on the principle that whole blood, contacting the surface of proper designed sorbent, would be cleared of certain substrates. With haemoadsorption it is possible to de-circulate from bloodstream high molecular weight substances, such as cytokines.

In this study Cytosorb® cartridge, based on haemoadsorption principle is applied on septic patients, suffering for acute kidney failure, along with continuous veno-venous haemodialysis (CVVH-D).

The immune system is involved in the pathogenesis of sepsis, but also the microcirculation has a crucial role in the natural history of this syndrome.

When a proinflammatory subset of cytokines is over-expressed, inducible nitric oxide synthase is activated and leads to an extra production on nitric oxide that results in a disrupted regulation of microvascular and capillary tone. The microcirculation plays a fundamental role to regulate gas, nutrients and metabolites exchange between bloodstream and cells. When microvascular perfusion is altered, tissue hypoxia may occur and result in organ dysfunction.

Microcirculation analysis can be performed at the bedside using a non-invasive video microscopy technique.

The primary endpoint of the study is to verify an improvement in the density of microcirculatory vessels and in the quality of blood flow after exposure to Cytosorb®. These two parameters are well described synthetically by the Perfused Vessel Density (PVD).

As secondary endpoints the investigators will analyze the modification of microcirculatory blood flow after haemoadsorption therapy. The microvascular blood flow, described by the microvascular flow index (MFI), is altered in sepsis. MFI values go from 0 to 3, where 0 means absence of flow, and 3 continuous blood flow. In septic shock MFI generally results to be inferior than 2.6, which is the cut off value between normal and altered MFI. Increasing value of MFI is a sign of microcirculation good response to therapy.

The investigators will also evaluate peripheral tissue oxygenation during Cytosorb exposure using near infrared spectroscopy (NIRS, Inspectra model 560 Hutchinson®). This technique evaluates microvascular perfusion on the thenar eminence muscle. A vascular occlusion test, that reproduces a stagnant ischemia condition, is performed to evaluate microvascular reactivity to an ischemia-reperfusion insult.

An improvement in tissue perfusion and microvascular reactivity is expected during the treatment.

Invasive haemodynamic monitoring will be performed using Picco2®. Changes in macro-haemodynamic parameters are expected in response to therapy.

The Sequential Organ Failure Assessment (SOFA) score will be calculated at the enrollment in this study and during the therapy.

Heart rate, SpO2, temperature, mean arterial pressure, arterial and central venous blood gas analyses will be collected during the study.

Materials and methods

In this prospective observational non interventional study, 10 septic patients with an acute kidney failure that need continuous veno-venous haemodialysis will be enrolled.

Prior to enrollment a formal informed consent is obtained. This study is approved by the local ethical committee.

Statistical analysis

The Kolmogorov-Smirnov test will be performed to define the normal or non-normal distribution of the variables. The ANOVA test for repeated measures with Bonferroni post hoc test or Dunn's post hoc test will be applied to evaluate differences over time. The Friedman test will be applied for not normally distributed data.

Blood sampling

At baseline (T0) participants will undergo arterial blood gas analysis to obtain the following values: arterial O2 tension (PaO2), arterial carbon dioxide tension, pH, base excess, lactate concentration, PaO2/FiO2 ratio, and central venous gas analysis to determine central venous O2 saturation.

The plasmatic concentration of the main pleiotropic cytokines will be measured, including interleukin (IL)1-beta, IL6, IL8, IL10, tumor necrosis factor-alpha.

After enrollment, these essay will be repeated at T1 (after 6h of exposure to Cytosorb®) and at T2 after 24h of therapy.

Routine blood cell count, clotting profile and leukocyte formula will be performed at baseline and at T2 along with proCalcitonine essay.

Microcirculation analysis

The investigators will analyse the microcirculation using sidestream dark field video microscopy technique applied to the sublingual mucosa, this technique is not invasive and painless.

In this study the investigators will use the Microscan by Microvision Medical (The Netherlands).

Three short videos of the microcirculation will be collected, captured in three different areas of the sublingual mucosa. These videos will be analysed using Automated Vascular Analysis (AVA 3.2 software, Microvision Medical, Amsterdam, NL). Microcirculation density is described by Total Vessel Density (TVD) and the De Backer score; microcirculation quality of flow is defined by the Microvascular flow index (MFI) and Percentage of Perfused Vessel (PPV). The Perfused Vessel Density (PVD) describes the density of well perfused vessel. Microcirculation analysis will be performed at T0, T1 and T2.

Tissue oxygenation

Tissue oxygenation will be assessed using near infrared spectroscopy (NIRS) applied on the thenar eminence muscle.

The device Inspectra® (Hutchinson model 560) measures the tissue oxygen saturation, and estimates the tissue haemoglobin content that is summarized in the tissue haemoglobin index (THI).

A vascular occlusion test will be performed, which simulates an ischemia-reperfusion condition of the tissue in order to evaluate microvascular reactivity.

A cuff is applied to the forearm and inflated at 300 mmHg in order to generate a stagnant ischemia. Inspectra screen generates a curve of desaturation named Downslope. When a value of tissue O2 saturation of 40% is reached, the occlusion cuff is deflated and the Inspector screen draws a curve of resaturation of the tissue, named Upslope. Upslope and Downslope values are measured. In the phase of resaturation an Hyperemia Area is obtained as tissue O2 saturation generally exceeds for a certain period of time the basal value. The hyperemia area is measured as an index of microvascular reactivity.

NIRS with a vascular occlusion test will be performed at T0, T1 and T2.

Haemodynamic monitoring

Each participant will undergo haemodynamic monitoring with transpulmonary thermodilution based devices (Picco2® by Pulsion and EV1000® by Edwards). Thermodilution based calibration are obtained ad basal time, at T1 and T2.

Vasopressor dose, haemodynamic parameters and SOFA score will be recorded at t0, t1, t2..

Conditions
Septic Shock
Being tested
Haemoadsorption with Cytosorb cartridge
Keywords
septic shock, microcirculation, acute renal failure, renal replacement therapy, haemoadsorption
Medical subject headings
Shock, Septic, Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Haemoadsorption with Cytosorb cartridgeDevice

    microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge

Study groups in NCT03456180
Study groupRoleWhat they receive
Haemoadsorption with Cytosorb cartridgepatients with septic shock and acute renal failure requiring renal replacement therapy with the haemoadsorption cartridge Cytosorb
Receives: Device: Haemoadsorption with Cytosorb cartridge

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. improvement in perfused vessel density

    improvement in perfusion of the sublingual microcirculation

    Measured: 24 hours

Secondary outcomes (3)
  1. improvement in microvascular flow index

    improvement in microvascular blood flow quality

    Measured: 6 hours and 24 hours

  2. improvement in tissue oxygenation

    improvement in NIRS-derived parameters of tissue oxygenation and microvascular reactivity

    Measured: 6 hours and 24 hours

  3. improvement in perfused vessel density

    improvement in perfusion of the sublingual microcirculation

    Measured: 6 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Mar 2018
  2. Study start9 Dec 2016
  3. Primary completion15 Dec 2017
  4. Study completion15 Dec 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03456180
Sponsor's protocol ID
cyto2018
Status last verified
Mar 2018
First submitted
28 Feb 2018
Last updated
8 Mar 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes

Publications

  • Malacarne P, Stella A, Giudici D, Bertolini G. [Infection surveillance in intensive care units. Preliminary results of a multicenter GiViTI study in 71 Italian ICUs]. Minerva Anestesiol. 2004 May;70(5):321-8. Italian.

    PubMed 15181412
  • Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006 Sep 7;355(10):1018-28. doi: 10.1056/NEJMoa063842. Epub 2006 Aug 14.

    PubMed 16908486
  • Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med. 2009 May;15(5):496-7. doi: 10.1038/nm0509-496.

    PubMed 19424209
  • Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, Cardona X, Inguaggiato P, Pilotto L, d'Intini V, Bellomo R. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003 Sep;27(9):792-801. doi: 10.1046/j.1525-1594.2003.07289.x.

    PubMed 12940901
  • Honore PM, Matson JR. Extracorporeal removal for sepsis: Acting at the tissue level--the beginning of a new era for this treatment modality in septic shock. Crit Care Med. 2004 Mar;32(3):896-7. doi: 10.1097/01.ccm.0000115262.31804.46. No abstract available.

    PubMed 15090989
  • Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs. 2005 Aug;28(8):777-86. doi: 10.1177/039139880502800803.

    PubMed 16211527
  • Peng Z, Singbartl K, Simon P, Rimmele T, Bishop J, Clermont G, Kellum JA. Blood purification in sepsis: a new paradigm. Contrib Nephrol. 2010;165:322-328. doi: 10.1159/000313773. Epub 2010 Apr 20.

    PubMed 20427984
  • Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009 Jun 17;301(23):2445-52. doi: 10.1001/jama.2009.856.

    PubMed 19531784
  • Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, Remuzzi G; GiViTI: Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva (Italian Group for the Evaluation of Interventions in Intensive Care Medicine) is an independent collaboration network of Italian Intensive Care units. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open. 2014 Jan 8;4(1):e003536. doi: 10.1136/bmjopen-2013-003536.

    PubMed 24401721
  • Ince C. The microcirculation is the motor of sepsis. Crit Care. 2005;9 Suppl 4(Suppl 4):S13-9. doi: 10.1186/cc3753. Epub 2005 Aug 25.

    PubMed 16168069
  • Sakr Y, Dubois MJ, De Backer D, Creteur J, Vincent JL. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med. 2004 Sep;32(9):1825-31. doi: 10.1097/01.ccm.0000138558.16257.3f.

    PubMed 15343008
  • Goedhart PT, Khalilzada M, Bezemer R, Merza J, Ince C. Sidestream Dark Field (SDF) imaging: a novel stroboscopic LED ring-based imaging modality for clinical assessment of the microcirculation. Opt Express. 2007 Nov 12;15(23):15101-14. doi: 10.1364/oe.15.015101.

    PubMed 19550794
  • Boushel R, Langberg H, Olesen J, Gonzales-Alonzo J, Bulow J, Kjaer M. Monitoring tissue oxygen availability with near infrared spectroscopy (NIRS) in health and disease. Scand J Med Sci Sports. 2001 Aug;11(4):213-22. doi: 10.1034/j.1600-0838.2001.110404.x.

    PubMed 11476426
  • De Backer D, Hollenberg S, Boerma C, Goedhart P, Buchele G, Ospina-Tascon G, Dobbe I, Ince C. How to evaluate the microcirculation: report of a round table conference. Crit Care. 2007;11(5):R101. doi: 10.1186/cc6118.

    PubMed 17845716
  • Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003 Apr;29(4):530-8. doi: 10.1007/s00134-003-1662-x. Epub 2003 Mar 28.

    PubMed 12664219

Questions about this trial

What is this clinical trial studying?

An observational study of Septic Shock, run by Università Politecnica delle Marche.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

improvement in perfused vessel density (time frame: 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03456180, which also lists 15 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Mar 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in